标题/作者	年份
2021 ESC Guidelines on cardiovascular disease prevention in clinical practice: Developed by the Task Force for cardiovascular disease prevention in clinical practice with representatives of the European Society of Cardiology and 12 medical societies With the special contribution of the European Association of Preventive Cardiology (EAPC) FLJ Visseren, F Mach, YM Smulders, D Carballo, KC Koskinas, M Bäck, ... European journal of preventive cardiology 29 (1), 5-115	2022
Effect of finerenone on chronic kidney disease outcomes in type 2 diabetes GL Bakris, R Agarwal, SD Anker, B Pitt, LM Ruilope, P Rossing, P Kolkhof, ... New England Journal of Medicine 383 (23), 2219-2229	2020
2021 guideline for the prevention of stroke in patients with stroke and transient ischemic attack: a guideline from the American Heart Association/American Stroke Association DO Kleindorfer, A Towfighi, S Chaturvedi, KM Cockroft, J Gutierrez, ... Stroke 52 (7), e364-e467	2021
9. Pharmacologic approaches to glycemic treatment: Standards of Medical Care in Diabetes—2020 American Diabetes Association Diabetes care 43 (Supplement_1), S98-S110	2020
9. Pharmacologic approaches to glycemic treatment: Standards of Medical Care in Diabetes—2021 American Diabetes Association Diabetes care 44 (Supplement_1), S111-S124	2021
Association of SGLT2 inhibitors with cardiovascular and kidney outcomes in patients with type 2 diabetes: a meta-analysis DK McGuire, WJ Shih, F Cosentino, B Charbonnel, DZI Cherney, ... JAMA cardiology 6 (2), 148-158	2021
Tirzepatide versus semaglutide once weekly in patients with type 2 diabetes JP Frías, MJ Davies, J Rosenstock, FC Pérez Manghi, L Fernández Landó, ... New England Journal of Medicine 385 (6), 503-515	2021
KDIGO 2020 clinical practice guideline for diabetes management in chronic kidney disease IH de Boer, ML Caramori, JCN Chan, HJL Heerspink, C Hurst, K Khunti, ... Kidney international 98 (4), S1-S115	2020
GLP-1 receptor agonists in the treatment of type 2 diabetes–state-of-the-art MA Nauck, DR Quast, J Wefers, JJ Meier Molecular metabolism 46, 101102	2021
Semaglutide 2· 4 mg once a week in adults with overweight or obesity, and type 2 diabetes (STEP 2): a randomised, double-blind, double-dummy, placebo-controlled, phase 3 trial M Davies, L Færch, OK Jeppesen, A Pakseresht, SD Pedersen, ... The Lancet 397 (10278), 971-984	2021
SGLT2 inhibitors: mechanisms of cardiovascular benefit beyond glycaemic control MR Cowie, M Fisher Nature Reviews Cardiology 17 (12), 761-772	2020
Efficacy and safety of a novel dual GIP and GLP-1 receptor agonist tirzepatide in patients with type 2 diabetes (SURPASS-1): a double-blind, randomised, phase 3 trial J Rosenstock, C Wysham, JP Frías, S Kaneko, CJ Lee, LF Landó, H Mao, ... The Lancet 398 (10295), 143-155	2021
9. Pharmacologic approaches to glycemic treatment: standards of medical care in diabetes-2022 B Draznin, VR Aroda, G Bakris, G Benson, FM Brown, RS Freeman, ... Diabetes care 45 (Suppl 1), S125-S143	2022
2020 expert consensus decision pathway on novel therapies for cardiovascular risk reduction in patients with type 2 diabetes: a report of the American College of Cardiology Solution Set Oversight Committee SR Das, BM Everett, KK Birtcher, JM Brown, JL Januzzi Jr, RR Kalyani, ... Journal of the American College of Cardiology 76 (9), 1117-1145	2020
Type 2 diabetes mellitus: a review of multi-target drugs A Artasensi, A Pedretti, G Vistoli, L Fumagalli Molecules 25 (8), 1987	2020
Management of hyperglycemia in type 2 diabetes, 2022. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD) MJ Davies, VR Aroda, BS Collins, RA Gabbay, J Green, NM Maruthur, ... Diabetes care 45 (11), 2753-2786	2022
Executive summary of the 2020 KDIGO Diabetes Management in CKD Guideline: evidence-based advances in monitoring and treatment IH de Boer, ML Caramori, JCN Chan, HJL Heerspink, C Hurst, K Khunti, ... Kidney international 98 (4), 839-848	2020
9. Pharmacologic approaches to glycemic treatment: Standards of Medical Care in Diabetes—2022 American Diabetes Association Professional Practice Committee, ... Diabetes Care 45 (Supplement_1), S125-S143	2022
Tirzepatide versus insulin glargine in type 2 diabetes and increased cardiovascular risk (SURPASS-4): a randomised, open-label, parallel-group, multicentre, phase 3 trial S Del Prato, SE Kahn, I Pavo, GJ Weerakkody, Z Yang, J Doupis, ... The Lancet 398 (10313), 1811-1824	2021
Akkermansia muciniphila secretes a glucagon-like peptide-1-inducing protein that improves glucose homeostasis and ameliorates metabolic disease in mice HS Yoon, CH Cho, MS Yun, SJ Jang, HJ You, J Kim, D Han, KH Cha, ... Nature Microbiology 6 (5), 563-573	2021

1 - 20

计算机程序会自动估算并确定日期和引用次数。